Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 195

1.

Advances in the biology of malignant pleural mesothelioma.

Zucali PA, Ceresoli GL, De Vincenzo F, Simonelli M, Lorenzi E, Gianoncelli L, Santoro A.

Cancer Treat Rev. 2011 Nov;37(7):543-58. doi: 10.1016/j.ctrv.2011.01.001. Epub 2011 Feb 1. Review.

PMID:
21288646
2.

Biology and management of malignant pleural mesothelioma.

Zucali PA, Giaccone G.

Eur J Cancer. 2006 Nov;42(16):2706-14. Epub 2006 Sep 20. Review.

PMID:
16989994
3.

Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand?

Agarwal V, Lind MJ, Cawkwell L.

Cancer Treat Rev. 2011 Nov;37(7):533-42. doi: 10.1016/j.ctrv.2010.11.004. Epub 2010 Dec 22. Review.

PMID:
21183281
4.

Advances in the systemic therapy of malignant pleural mesothelioma.

Fennell DA, Gaudino G, O'Byrne KJ, Mutti L, van Meerbeeck J.

Nat Clin Pract Oncol. 2008 Mar;5(3):136-47. doi: 10.1038/ncponc1039. Review.

PMID:
18227828
5.

Review on clinical trials of targeted treatments in malignant mesothelioma.

Jakobsen JN, Sørensen JB.

Cancer Chemother Pharmacol. 2011 Jul;68(1):1-15. doi: 10.1007/s00280-011-1655-3. Epub 2011 May 7. Review.

PMID:
21553148
6.

Hyaluronan content in pleural fluid as a prognostic factor in patients with malignant pleural mesothelioma.

Thylén A, Hjerpe A, Martensson G.

Cancer. 2001 Sep 1;92(5):1224-30.

PMID:
11571736
7.

Targeted therapies in malignant pleural mesothelioma: a review of clinical studies.

Greillier L, Marco S, Barlesi F.

Anticancer Drugs. 2011 Mar;22(3):199-205. doi: 10.1097/CAD.0b013e328341ccdd. Review.

PMID:
21263312
8.

Malignant pleural mesothelioma.

Kindler HL.

Curr Treat Options Oncol. 2000 Oct;1(4):313-26. Review.

PMID:
12057157
9.

Induction of apoptosis by intrapleural perfusion hyperthermo-chemotherapy for malignant pleural mesothelioma.

Matsuzaki Y, Tomita M, Shimizu T, Hara M, Ayabe T, Onitsuka T.

Ann Thorac Cardiovasc Surg. 2008 Jun;14(3):161-5.

PMID:
18577894
10.

High doses of intrapleural cisplatin in a case of malignant pleural mesothelioma. Clinical observations and pharmacokinetic analyses.

Lerza R, Esposito M, Vannozzi M, Bottino GB, Bogliolo G, Pannacciulli I.

Cancer. 1994 Jan 1;73(1):79-84.

11.

Cytokeratin 19 fragment/carcinoembryonic antigen ratio in pleural effusion is a useful marker for detecting malignant pleural mesothelioma.

Suzuki H, Hirashima T, Kobayashi M, Sasada S, Okamoto N, Uehara N, Tamiya M, Matsuura Y, Morishita N, Kawase I.

Anticancer Res. 2010 Oct;30(10):4343-6.

PMID:
21036761
12.

Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma.

Hirayama N, Tabata C, Tabata R, Maeda R, Yasumitsu A, Yamada S, Kuribayashi K, Fukuoka K, Nakano T.

Respir Med. 2011 Jan;105(1):137-42. doi: 10.1016/j.rmed.2010.10.010. Epub 2010 Oct 30.

13.

Translational therapies for malignant pleural mesothelioma.

Belli C, Anand S, Tassi G, Fennell D, Mutti L.

Expert Rev Respir Med. 2010 Apr;4(2):249-60. doi: 10.1586/ers.10.17. Review.

PMID:
20406091
14.

Malignant pleural mesothelioma: current treatments and emerging drugs.

Belli C, Fennell D, Giovannini M, Gaudino G, Mutti L.

Expert Opin Emerg Drugs. 2009 Sep;14(3):423-37. doi: 10.1517/14728210903074563. Review.

PMID:
19552609
15.

Systemic approach to malignant pleural mesothelioma: what news of chemotherapy, targeted agents and immunotherapy?

Signorelli D, Macerelli M, Proto C, Vitali M, Cona MS, Agustoni F, Zilembo N, Platania M, Trama A, Gallucci R, Ganzinelli M, Pelosi G, Pastorino U, de Braud F, Garassino MC, Lo Russo G.

Tumori. 2016 Jan-Feb;102(1):18-30. doi: 10.5301/tj.5000436. Epub 2015 Oct 14. Review.

PMID:
26481865
16.

Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma.

Hartman ML, Esposito JM, Yeap BY, Sugarbaker DJ.

J Thorac Cardiovasc Surg. 2010 May;139(5):1233-40. doi: 10.1016/j.jtcvs.2009.06.027. Epub 2009 Oct 22.

17.

Pemetrexed therapy for malignant pleural mesothelioma.

Puto K, Garey JS.

Ann Pharmacother. 2005 Apr;39(4):678-83. Epub 2005 Mar 8. Review.

PMID:
15755794
18.

Molecular targets in malignant pleural mesothelioma treatment.

Pasello G, Favaretto A.

Curr Drug Targets. 2009 Dec;10(12):1235-44. Review.

PMID:
19909234
19.

Clinical significance of the expression of tumor-associated antigen, RCAS1, and its soluble protein in pleural fluid in malignant mesothelioma.

Hiraki A, Aoe K, Murakami T, Nakamura Y, Yamazaki K, Sueoka N, Taguchi K, Kamei T, Maeda T, Takeyama H, Kishimoto T, Nishimura M, Sugi K.

Oncol Rep. 2005 Aug;14(2):357-62.

PMID:
16012715
20.

The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro.

Cole GW Jr, Alleva AM, Reddy RM, Maxhimer JB, Zuo J, Schrump DS, Nguyen DM.

J Thorac Cardiovasc Surg. 2005 May;129(5):1010-7.

Supplemental Content

Support Center